Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Company profile
Ticker
NVS, NVSEF
Exchange
Website
CEO
Vasant Narasimhan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVS stock data
Latest filings (excl ownership)
SC TO-T/A
Third party tender offer statement (amended)
25 Apr 24
6-K
Current report (foreign)
23 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
18 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
17 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
16 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
15 Apr 24
SC TO-T
Third party tender offer statement
11 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 24
SC TO-C
Information about tender offer
6 Feb 24
SC TO-C
Information about tender offer
5 Feb 24
Transcripts
NVS
Earnings call transcript
2022 Q2
19 Jul 22
NVS
Earnings call transcript
2022 Q1
26 Apr 22
NVS
Earnings call transcript
2021 Q4
2 Feb 22
NVS
Earnings call transcript
2021 Q3
26 Oct 21
NVS
Earnings call transcript
2021 Q2
21 Jul 21
NVS
Earnings call transcript
2020 Q3
27 Oct 20
NVS
Earnings call transcript
2020 Q3
27 Oct 20
Latest ownership filings
SC 13D
MorphoSys AG
18 Apr 24
SC 13G/A
BlackRock Inc.
2 Feb 24
144
Notice of proposed sale of securities
19 Sep 23
SC 13G/A
BlackRock Inc.
1 Feb 23
3
PHARMA AG NOVARTIS
27 Jun 22
SC 13G
BlackRock Inc.
4 Feb 22
SC 13G/A
XOMA Corp
19 Aug 20
3
Cellular Biomedicine Group, Inc.
14 Aug 20
4
PHARMA AG NOVARTIS
16 Jul 20
3
PHARMA AG NOVARTIS
13 Jul 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
5.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1035 |
Opened positions | 112 |
Closed positions | 245 |
Increased positions | 322 |
Reduced positions | 356 |
13F shares | Current |
---|---|
Total value | 10.42 tn |
Total shares | 115.23 mm |
Total puts | 90.20 k |
Total calls | 181.00 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Dodge & Cox | 13.17 mm | $1.33 tn |
Primecap Management | 12.91 mm | $1.30 tn |
MS Morgan Stanley | 7.09 mm | $716.10 bn |
Dimensional Fund Advisors | 6.08 mm | $613.70 bn |
Loomis Sayles & Co L P | 6.01 mm | $606.82 mm |
BEN Franklin Resources | 5.91 mm | $597.24 bn |
Wellington Management | 4.75 mm | $479.26 bn |
GS Goldman Sachs | 3.54 mm | $357.02 bn |
Renaissance Technologies | 2.84 mm | $286.56 mm |
PFG Principal Financial Group Inc - Registered Shares | 2.51 mm | $253.30 bn |
News
What's Going On With Pfizer Stock On Thursday?
25 Apr 24
Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
25 Apr 24
BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116
24 Apr 24
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
24 Apr 24
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
23 Apr 24
Press releases
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
15 Apr 24
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 Apr 24
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
6 Apr 24
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24